Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calderasib PK in Renal Impairment
NCT06814119Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of calderasib in cancer (3 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve From Time 0 to Infinity at 2 days, Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration at 2 days and 7 more. Started Apr 2025; status: completed.
02
Drugs
calderasib
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06814119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06814119.